CHR in the media: March/April 2019

In late March, Lisa Rapaport interviewed Dr. Gleicher for her article on Reuters about the reported higher risk of cancer among children born from IVF. Dr. Gleicher pointed out that this may be a result of chromosomal instabilities related to maternal age rather than a direct effect of IVF and patients should not prematurely forego fertility treatment.

In mid-April, Dr. Gleicher was an invited participant at a roundtable discussion on genetic editing, held by Harvard Law School‘s Petrie-Flom Center. New York Times ran an editorial on the issue, arguing that mitochondrial replacement therapy should at least be considered for an exception to the federal ban on human gene editing.

This is a part of the April 2019 CHR VOICE.

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.